No Data
No Data
Guotou Securities: The market share of listed pharmacies continues to increase, and the growth potential is expected to lead the industry.
In the context of a slowdown in the industry's growth rate, listed pharmacies are expected to achieve growth rates higher than the industry by virtue of their continuous rapid expansion of stores.
ARK Health (06086.HK): stable pricing action, end of stable pricing period and expiration of excess share subscription rights.
On August 5th, Guolonghui announced that the stable price period for global sales of Ark Pharmacy (06086.HK) has ended on August 3rd, 2024 (i.e. 30 calendar days from the deadline for submitting the Hong Kong public offering application). The overall coordinator (for itself and on behalf of international underwriters) did not exercise the over-allotment option, which expired on August 3rd, 2024.
Carrying on traditions and innovation, Ark Pharmacy collaborates with Guangzhou Baiyunshan to create a digital medical and health intelligence blueprint.
Arca Health and Guangzhou Baiyunshan collaborate to create a digital medical and health intelligence blueprint.
Stock market anomaly: Ark Pharmacy (06086) rebounded more than 20% on the second day of listing, still falling by 30% compared to the IPO price. It has accumulated losses of nearly 0.9 billion yuan in the past three years.
According to the Zhītōng Cáijīng app, Ark Pharmacy (06086) fell over 44% yesterday and rebounded over 20% in early trading today. The current stock price still fell 30% from the offer price. As of press time, it rose 17%, to HKD 5.3, with a turnover of HKD 11.1438 million. It is reported that Ark Pharmacy focuses on the management of chronic diseases (such as hypertension, cardiovascular, respiratory system, etc.), provides comprehensive and all-round management services for chronic diseases, and provides comprehensive medical services and online retail pharmacy services through the Jianke platform. According to the information from Zhuó Shí Zīxún, based on the average monthly active users in 2023, the company is China's largest online chronic disease management platform.
Why can't Farlong Pharmaceuticals (06086) tell the story of H2H despite the dark market crash and the waist-cutting of the listing?
Wearing the title of "the largest internet plus-related chronic disease management platform in China", Ark Pharmacy (06086) officially listed on the Hong Kong Stock Exchange on July 9th. However, this title seems to have brought little benefit to the company, as the opening price dropped by nearly 50%, showing the "other passion" from the capital markets.
Hong Kong stocks closed (07.09) | HSI flat, Apple suppliers and semiconductor stocks strong throughout the day, cnbm (03323) plummeted 13% after warning of earnings.
In the morning trading, the three major Hong Kong stock indices showed weak volatility. They all rose and turned red at noon, but then struggled to rise. The Hang Seng Index and the National Index successively fell, only the Hang Seng China Enterprise Index achieved growth.
No Data